WASHINGTON – Consumer health advocates and a patent holder on a highly anticipated blood thinner from Eli Lilly want the Food and Drug Administration to halt its review of the drug, which they say may be unsafe at the suggested dose.
The FDA has been reviewing Indianapolis-based Lilly's prasugrel since January 2008. A company study showed the drug prevents more heart attacks than an older drug, but also causes more internal bleeding.
Consumer watchdog Public Citizen and a research professor who holds a patent on the drug contend that the dose used in that study led to the excess bleeding. They ask the agency to halt its review until new studies are completed.